US Stock MarketDetailed Quotes

ALMS Alumis

Watchlist
  • 7.520
  • -0.540-6.70%
Close Dec 30 16:00 ET
  • 7.890
  • +0.370+4.92%
Post 20:01 ET
409.14MMarket Cap-1.71P/E (TTM)

About Alumis Company

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Company Profile

SymbolALMS
Company NameAlumis
Listing DateJun 28, 2024
Issue Price16.00
Founded2021
CEOMr. Martin Babler
MarketNASDAQ
Employees109
Fiscal Year Ends12-31
Address280 East Grand Avenue
CitySan Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080
Phone1-650-231-6625
Websitehttp://www.alumis.com

Company Executives

  • Name
  • Position
  • Salary
  • Martin Babler
  • Chairman of the Board, President and Chief Executive Officer
  • 4.59M
  • Roy C. Hardiman
  • Chief Business and Legal Officer
  • 1.04M
  • Dr. David M. Goldstein, PhD
  • Chief Scientific Officer
  • 1.04M
  • Dr. Jorn Drappa, M.D.,PhD
  • Chief Medical Officer
  • --
  • John R. Schroer
  • Chief Financial Officer
  • --
  • Mark Bradley
  • Chief Development Officer
  • --
  • Derrick Richardson
  • Senior Vice President, People and Culture
  • --
  • Dr. Alan B. Colowick, M.D.,M.P.H.
  • Independent Director
  • --
  • Dr. Zhengbin Yao, PhD
  • Independent Director
  • --
  • Patrick C. Machado, J.D.
  • Independent Director
  • --
  • Dr. Srinivas Akkaraju, M.D.,PhD
  • Independent Director
  • --
  • Dr. Sapna Srivastava, PhD
  • Independent Director
  • --
  • Dr. James B. Tananbaum,M.D.
  • Independent Director
  • --
  • Sara Klein
  • General Counsel and Corporate Secretary
  • --
Heat List
US
Overall
Symbol
Price
% Chg

No Data